Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Tenaya Therapeutics Announces Pricing Details for Underwritten Offering

Elaine Mendonca by Elaine Mendonca
February 8, 2024
in Breaking News
0
Biotechnology Stock Exchange
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has recently unveiled the pricing details of its underwritten offering, set to take place on or around February 12, 2024. The offering consists of 8,888,890 shares of its common stock, priced at $4.50 per share. Additionally, the offering includes pre-funded warrants, allowing the purchase of up to 2,222,271 shares of common stock at a purchase price of $4.499 per warrant. This offering is expected to generate total gross proceeds of approximately $50 million for Tenaya Therapeutics, Inc.

Leerink Partners and TD Cowen have been appointed as the underwriters for this offering. Notably, both new and existing investors have participated in the offering. Prominent investors include The Column Group, RA Capital Management, Venrock Healthcare Capital Partners, Octagon Capital, funds and accounts managed by BlackRock, Armistice Capital, Integral Health Asset Management, PFM Health Sciences, LP, and Soleus Capital, along with two large investment management firms.

Before accounting for underwriting discounts, commissions, and offering expenses, Tenaya Therapeutics, Inc. anticipates receiving total gross proceeds of approximately $50 million from this offering.

Promising Performance of TNYA Stock on February 8, 2024: Strong Momentum and Potential for Growth

On February 8, 2024, TNYA stock showed promising performances as it traded in the middle of its 52-week range and above its 200-day simple moving average. These indicators suggest that the stock was in a relatively stable position and had potential for further growth.

The price of TNYA shares experienced a significant increase of $0.71 since the market last closed. This represents a rise of 16.06%, which is quite impressive. Closing at $5.13, the stock showed strong momentum and investor confidence.

However, it is worth noting that after-hours trading saw a slight drop in the stock price. TNYA stock decreased by $0.17 during this period. While this drop may be seen as a minor setback, it is important to consider the overall trend and the context in which it occurred.

Overall, TNYA stock had a positive performance on February 8, 2024. The significant increase in price and the fact that it was trading above its 200-day simple moving average indicate that investors had confidence in the stock. Despite the slight drop in after-hours trading, the stock’s overall momentum suggests that it may continue to perform well in the near future.

Investors should keep an eye on TNYA stock and monitor its movements closely. It is advisable to consider additional factors such as market trends, company news, and financial reports before making any investment decisions.

TNYA Stock Performance: Mixed Indicators and Potential Signs of Recovery

On February 8, 2024, TNYA stock experienced a mixed performance, with some positive and negative indicators. According to data from CNN Money, TNYA reported a net income of -$123.67 million over the past year, representing a significant decrease of 70.05% compared to the previous year. However, TNYA’s net income for the third quarter of the same year was -$29.14 million, indicating a 12.4% increase compared to the previous quarter. The earnings per share (EPS) for TNYA was -$2.76 over the past year, a decline of 56.65% compared to the previous year. However, there was a slight improvement in the third quarter, with an EPS of -$0.39, indicating a 13.04% increase compared to the previous quarter. These figures highlight both positive and negative aspects of TNYA’s financial performance, with concerns about profitability but potential signs of recovery. The absence of total revenue data limits a comprehensive assessment of TNYA’s financial health, and investors and analysts should closely monitor the company’s financial reports and announcements for a more accurate understanding of its performance. Thorough research and analysis, as well as consultation with financial professionals, are essential before making any investment decisions.

Tags: TNYA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Replimune Group Inc Reports Surprising Q3 Results and Strong Financial Position

Food Producers Stock Market Today

Kellogg Announces Impressive Quarterly Sales and Earnings Performance

Patrick Industries Reports Quarterly Financial Results Exceeding Expectations but Showing Significant Decline Compared to Previous Year

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com